© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
January 19, 2021
No significant benefits to progression-free survival were noted with the axitinib-plus-octreotide combination for the treatment of patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.
December 10, 2020
After breast-conserving surgery and adjuvant endocrine therapy, whole breast irradiation can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years.
December 06, 2020
The enriched chimeric antigen receptor T-cell therapy improved responses and prolonged duration of response in patients with relapsed/refractory multiple myeloma.
June 07, 2020
The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.